HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention - Wikidata - wikimedia - TriplyDB

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

http://www.wikidata.org/entity/Q27666355

about

HIV type 1 Gag as a target for antiviral therapy HIV-1 capsid: the multifaceted key player in HIV-1 infection The choreography of HIV-1 proteolytic processing and virion assembly Time-Resolved Imaging of Single HIV-1 Uncoating In Vitro and in Living Cells Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication.CPSF6 Defines a Conserved Capsid Interface that Modulates HIV-1 Replication Structure of a Monomeric Mutant of the HIV-1 Capsid Protein Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein Discovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid Complexes HIV-1 evades innate immune recognition through specific cofactor recruitment Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine series Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing Direct binding of a hepatitis C virus inhibitor to the viral capsid protein Large-scale functional purification of recombinant HIV-1 capsid All-Atom Molecular Dynamics of Virus Capsids as Drug Targets Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids.STRUCTURAL VIROLOGY. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability.Structural basis of HIV-1 capsid recognition by PF74 and CPSF6.Characterization of the mode of action of a potent dengue virus capsid inhibitor High-throughput profiling of point mutations across the HIV-1 genome.Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development.Direct visualization of HIV-1 with correlative live-cell microscopy and cryo-electron tomography.MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1 Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.Production and purification of polymerization-competent HIV-1 capsid protein p24 (CA) in NiCo21(DE3) Escherichia coli.BI-2 destabilizes HIV-1 cores during infection and Prevents Binding of CPSF6 to the HIV-1 Capsid A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid Extreme genetic fragility of the HIV-1 capsid.Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsid-targeting small-molecule inhibitor.Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity.Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy.In vitro analysis of human immunodeficiency virus particle dissociation: gag proteolytic processing influences dissociation kinetics.Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex.Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly.Microplate-based assay for identifying small molecules that bind a specific intersubunit interface within the assembled HIV-1 capsid.Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus.HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.HIV-1 capsid-targeting domain of cleavage and polyadenylation specificity factor 6

P2860

Q24614498-7E8C973B-5F4F-4728-AB0C-DD56E5B21DDB Q26801145-F65E6127-7925-48D3-AE6F-9A26850F0A50 Q27009643-563DDCC1-AF20-4FD2-B179-67641CBF9105 Q27313409-7A7C9C9D-F7D8-4182-8C41-B655CDB2423A Q27324193-9842377E-0084-49B0-8929-3CDA93074043 Q27672646-83039ACD-D666-49CC-BB9D-23BA40308E36 Q27675009-4B9AB10C-2D3B-47FA-967D-A90860FBF5FC Q27678471-3A9D3933-9618-42B3-B34A-1947F2AF889C Q27678859-05C8DB37-C533-47F5-9584-2165774C0971 Q27680544-B9CFBF69-4911-4578-8905-3033161ED452 Q27683977-979773A1-2ABE-421D-B87F-CBB3EFB405DD Q28476840-ADA64AFC-F103-4F72-9F45-D39BD8EB512D Q28480389-6AEB16E9-946E-40E2-B722-B1FCCDE6B304 Q28481306-FD55AB9C-24A4-4D5E-B7DF-931F7431CCC2 Q28487670-65FABB77-F059-400D-A139-4BC927775F86 Q28833669-FABBF68D-2292-4BBB-BDE7-2E05322F5921 Q30276687-F16F7909-09AE-4EFF-9017-18B8975180D0 Q30279235-0C85C601-08D0-4936-9BB1-F061E7B69E54 Q30301100-F0E953DD-B9F4-4679-9699-DFC02257E652 Q30365058-49789EAD-851B-422C-A246-846FF1FD555A Q30369959-E2298BDA-5BC8-4EFE-9723-3C6BAE4BABA4 Q30381239-69DE1407-2DCD-41AA-856D-0EC5DB3A98A6 Q34073213-94FF4A64-4E3B-4D35-9ED7-B7233DDD7EF5 Q34091405-08FE5364-AE5E-47CB-B765-8083CE02ACF8 Q34179686-9678449F-E25A-40DE-A5A0-145CB8A30684 Q34529423-CC61563C-BB41-41BB-82CB-72948BDCF146 Q34738657-22A49DAE-6A97-486B-BA48-5B60C6E7AD33 Q34771244-EEB8F613-010C-485E-A11C-84D94ABF0059 Q34789351-EA4144F3-C164-4EB4-A226-B0856888D757 Q34989840-09359104-9F8A-4A30-A00E-BF833F6FB1FD Q34992565-B20C9F86-D918-4226-B86D-DD34F98ED9E3 Q35018068-AB251C36-C54C-4CC4-BBF6-24BCCAEB8B7D Q35024116-17F9A658-6B9C-45AA-AD3E-37EEC0B71A63 Q35184863-43C8AE6E-2E57-48B3-A6D9-EB32ACBAED74 Q35201628-30E4D83F-5CDB-404E-9C1E-F829C89F220C Q35377316-81F1EE05-351B-491B-9D61-E01F1238156D Q35664524-B884D479-88E8-4FBD-ACA0-251A2B3449AE Q35704078-F03A6C90-6241-44DD-8190-B0A26E0FE0AD Q35761626-DB0C3899-9389-4379-9D71-E3F428B70C16 Q35826918-3DD85F7D-8707-4555-97D5-F54BDAC63375

P2860

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

http://www.wikidata.org/entity/Q27666355

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@ast

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@en

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@nl

type

label

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@ast

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@en

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@nl

altLabel

HIV capsid is a tractable target for small molecule therapeutic intervention

@en

prefLabel

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@ast

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@en

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@nl

P1433

Q27666355-24F50E47-8886-48D8-ACEB-45558B7FD274

P1476

Q27666355-79408C0A-FC7A-449C-8ED8-B331AE535461

P2093

Q27666355-0440C933-4BB8-4559-94F4-96E80421FB97

Q27666355-1E599042-2171-45A7-A377-95BBCCDF64E8

Q27666355-2AB29B67-7FE6-4554-8481-83DFFA7D0D8D

Q27666355-4ACB107C-1081-4BF3-9931-3FBF0567DAAF

Q27666355-6DBDF8AD-5D82-4E2E-A639-BBAB488DC94A

Q27666355-86476805-E0E9-4780-AF6B-72D00F31F453

Q27666355-8D479EEC-8D27-41BA-B882-21B36C4C12AB

Q27666355-9672407F-754E-4A84-8C08-9B813D55C876

Q27666355-974742BE-AF1C-4DB1-A2B3-4E373D8E0975

Q27666355-9873D2A0-6EF3-4248-B1E6-A2107E63844E

P2860

Q27666355-0D2B69BC-8BA3-4BDD-9B79-7BA707430FB8

Q27666355-0FEF1931-DAC9-4026-B4D8-51E28BE2F6FC

Q27666355-15A754A0-7BEE-47F3-BE1B-9D7EE2E48569

Q27666355-2E7683D6-1B65-48CF-B3A0-8A677B7A582D

Q27666355-33034403-A557-4193-9E85-31E4AF6A2EA2

Q27666355-341B504D-23BC-4868-B4CC-9CBB992516FB

Q27666355-364490BC-C11C-42A6-AEF8-B7128FED31BC

Q27666355-39D0F6F7-C81E-411D-B92F-5A3C5327FF01

Q27666355-3A232E07-85F7-4BF0-9F5E-5E83DA6A190E

Q27666355-4DFDEE25-A72F-4A7B-9FA0-E0ACDAB38185

P304

Q27666355-D6772660-59ED-4D2D-8B89-F8902FD109F6

P31

Q27666355-D235DF3D-5947-4BA3-8AB3-050048153737

P3181

Q27666355-5E1E6E73-129F-44D8-B071-A03614FAE9BB

P356

Q27666355-9067770F-1A44-4EFA-85CE-91928CD990C9

P407

Q27666355-B4C73951-C11C-487E-8EAF-599F865D49C0

P433

Q27666355-7BFBAB28-1C33-4CF9-9F4E-AF9E293E9F07

P478

Q27666355-12BD2861-9E2C-4096-9458-00713362D813

P577

Q27666355-69E07B2B-F27A-464A-8EF1-F0F56D0D80B0

P5875

Q27666355-3AA79DFD-5D5A-454E-8B0F-169C76BDEE6D

P698

Q27666355-930F85D6-9EFC-4317-8126-C2BC7BBF2C20

P921

Q27666355-8449C98E-D103-4DE7-9748-05D4F78EF94E

P932

Q27666355-30856C32-F8A8-4173-905C-62DD7BD47870

P3181

P356

JOURNAL.PPAT.1001220

P1433

P1476

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

@en

P2093

Amy K Patick

http://www.w3.org/2001/XMLSchema#string

Andrew D Scott

http://www.w3.org/2001/XMLSchema#string

Anne Kjerrstrom

http://www.w3.org/2001/XMLSchema#string

Chris Pickford

http://www.w3.org/2001/XMLSchema#string

David G Brown

http://www.w3.org/2001/XMLSchema#string

Giuseppe Ciaramella

http://www.w3.org/2001/XMLSchema#string

Hua Wu

http://www.w3.org/2001/XMLSchema#string

James A Nieman

http://www.w3.org/2001/XMLSchema#string

Jason Isaacson

http://www.w3.org/2001/XMLSchema#string

Joan Cao

http://www.w3.org/2001/XMLSchema#string

P2860

Mutual conformational adaptations in antigen and antibody upon complex formation between an Fab and HIV-1 capsid protein p24

Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein

Structure of full-length HIV-1 CA: a model for the mature capsid lattice

Solution Structure of a Hydrocarbon Stapled Peptide Inhibitor in Complex with Monomeric C-terminal Domain of HIV-1 Capsid

X-ray structures of the hexameric building block of the HIV capsid.

Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid

Refinement of macromolecular structures by the maximum-likelihood method

The CCP4 suite: programs for protein crystallography

A peptide inhibitor of HIV-1 assembly in vitro.

A cell-penetrating helical peptide as a potential HIV-1 inhibitor.

P304

e1001220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

660739

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PPAT.1001220

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49694960

http://www.w3.org/2001/XMLSchema#string

P698

21170360

http://www.w3.org/2001/XMLSchema#string

P921

P932

3000358

http://www.w3.org/2001/XMLSchema#string